Pharmacogenomics in the Evaluation of Efficacy and Adverse Events During Clinical Development of Vaccines
2008 (English)In: Pharmacogenomics in Drug Discovery and Development: From Bench to Bedside / [ed] Yan, Qing, New York, NY, United States: Humana Press, 2008, 1, 469-479 p.Chapter in book (Other academic)
The field of pharmacogenomics arose to develop personalized medicine, or medicine that deals with the complexity of the human body. In this book, leading experts present methodical, state-of-the-art contributions covering topics from individual molecules to systemic diseases, examining both fundamental concepts and advanced technologies. The volume begins by exploring cutting-edge technologies used to pursue systems-based pharmacogenomics, followed by extensive chapters on gene-drug interactions and the use of pharmacogenomics in therapeutics of diseases. This book is ideal for scientists striving to transform disease treatment into disease prevention.
Place, publisher, year, edition, pages
New York, NY, United States: Humana Press, 2008, 1. 469-479 p.
, Methods in Molecular Biology, ISSN 1064-3745 ; 448
Adverse reactions; clinical study; efficacy; microarray; PBMCs; pharmacogenomics; vaccine
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
IdentifiersURN: urn:nbn:se:liu:diva-44951DOI: 10.1007/978-1-59745-205-2_17Local ID: 78431ISBN: 978-1-58829-887-4 (print)ISBN: 978-1-59745-205-2 (online)OAI: oai:DiVA.org:liu-44951DiVA: diva2:265813